Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Nuevolution Joins Drug Discovery Group

October 6, 2010 8:02 am | News | Comments

A consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and the research group of Professor Kristian Helin has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.


Cisbio Partners With Blue Sky

October 6, 2010 7:59 am | News | Comments

Cisbio Bioassays, member of IBA Group and global provider of HTRF (homogenous time resolved fluorescence) technology and services to facilitate new drug discovery, announces the signing of a partnership with Blue Sky BioProducts.


Serotonin Uses Special Pathway

October 6, 2010 7:44 am | News | Comments

Scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances.


HDL Controlling Drug Target Found

October 6, 2010 7:40 am | News | Comments

Thanks to a discovery by a Saint Louis University researcher, scientists have identified an important microRNA that may allow us to better control cholesterol levels in blood.


Benicar Superior to Cozaar in New Study

October 6, 2010 7:33 am | News | Comments

Patients treated with Benicar in BeniVICTOR study experienced significantly greater blood pressure reductions and higher goal attainment rates than patients treated with Cozaar after 8 weeks.


FDA Approves Additional Veletri Uses

October 6, 2010 7:28 am | News | Comments

Actelion Ltd announced that the U.S. Food and Drug Administration has approved additional in-use conditions for administration of Veletri, an improved formulation of epoprostenol.


GE Launches Heart-Muscle Tox Test

October 6, 2010 7:19 am | News | Comments

Geron says GE Healthcare is now selling a human cardiomyocyte-based toxicology screening product the companies developed together.


Three Win Nobel Prize Key Chemical Tool

October 6, 2010 7:13 am | by Karl Ritter | News | Comments

An American and two Japanese scientists won the Nobel Prize in chemistry for finding new ways to bond carbon atoms together, methods now widely used to make medicines and even slimmed-down computer screens.


FDA Warns Gilead on Manufacturing Issues

October 6, 2010 7:09 am | by Matthew Perrone | News | Comments

The Food and Drug Administration posted a warning letter on its website, outlining more than a half-dozen quality-control problems uncovered by inspectors on a routine visit to Gilead's San Dimas, Calif., facility.


Novartis Cancelling Two Drugs

October 6, 2010 7:06 am | News | Comments

Novartis AG said it will take a charge of $590 million during the third quarter as it discontinues development of a potential hepatitis C drug and an antifungal product.


Judge Approves $600M Botox Settlement

October 6, 2010 6:58 am | by Greg Bluestein | News | Comments

A federal investigation into Allergan Inc.'s misleading marketing of its wrinkle-smoothing Botox medication is over after a judge in Georgia approved the pharmaceutical firm's decision to pay $600 million and plead guilty to misbranding the product.


Pfizer May Sell Capsugel

October 6, 2010 6:54 am | News | Comments

Pfizer Inc. said it is reviewing its strategic alternatives for its Capsugel business unit, which makes hard capsules used to deliver medication.


J & J Acquiring Crucell for $2.4B

October 6, 2010 6:52 am | News | Comments

Johnson & Johnson said it is buying Crucell N.V. for about $2.41 billion in a move that will boost the American health care company's vaccine business.


Culture Surface

October 5, 2010 8:43 am | Product Releases | Comments

Thermo Fisher Scientific Inc. has introduced the Nunclon Vita stem cell culture surface. The energy-treated polystyrene surface enables direct attachment, colony formation, and growth of human embryonic stem cells and induced pluripotent stem cells.


Human Cardiomyocytes

October 5, 2010 8:29 am | Product Releases | Comments

GE Healthcare announces the availability of human cardiomyocytes that provide a more readily available and biologically-relevant alternative to current cell models and primary cells used in drug discovery and predictive toxicity testing.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.